CA Patent

CA2830511C — Pharmaceutical compositions comprising aripiprazole lauroxil and sorbitan laurate

Assigned to Alkermes Pharma Ireland Ltd · Expires 2021-09-14 · 5y expired

What this patent protects

The present application relates to a pharmaceutical composition comprising: (a) compound A-7: (b) sorbitan laurate; (c) polysorbate 20; and (d) an aqueous vehicle, where the composition forms an aqueous, flocculated, injectable suspension. The present application also relates to …

USPTO Abstract

The present application relates to a pharmaceutical composition comprising: (a) compound A-7: (b) sorbitan laurate; (c) polysorbate 20; and (d) an aqueous vehicle, where the composition forms an aqueous, flocculated, injectable suspension. The present application also relates to an injectable pharmaceutical composition comprising (a) compound A-7 in a weight ratio of 15 ¨ 35%; (b) sorbitan laurate in a weight ratio of 0.2 ¨ 1%; (c) polysorbate 20 in a weight ratio of 0.05 ¨ 0.8%; and (d) an aqueous carrier. The present application also relates to uses compositions for treating disorders of the central nervous system.

Drugs covered by this patent

Patent Metadata

Patent number
CA2830511C
Jurisdiction
CA
Classification
—
Expires
2021-09-14
Drug substance claim
No
Drug product claim
No
Assignee
Alkermes Pharma Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.